trabectedin,nivolumab,ipilimumab
otsuka,valeo pharmaceutical,pharmamar,bms
['nivo', 'nivolumab', 'congrat', ' ipi ', 'sarcoma', 'trabectedin']
promising efficacy data of the combination trabectedin plus ipi plus nivolumab in leiomyosarcoma in #esmo22!!!! more than 30% response rate with durable responses (almost 7 months) congratulations !